首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3236篇
  免费   265篇
  国内免费   87篇
耳鼻咽喉   15篇
儿科学   72篇
妇产科学   79篇
基础医学   460篇
口腔科学   24篇
临床医学   137篇
内科学   486篇
皮肤病学   53篇
神经病学   101篇
特种医学   48篇
外科学   422篇
综合类   282篇
现状与发展   1篇
预防医学   225篇
眼科学   19篇
药学   550篇
  5篇
中国医学   118篇
肿瘤学   491篇
  2024年   3篇
  2023年   38篇
  2022年   61篇
  2021年   102篇
  2020年   127篇
  2019年   119篇
  2018年   95篇
  2017年   108篇
  2016年   115篇
  2015年   104篇
  2014年   146篇
  2013年   235篇
  2012年   128篇
  2011年   153篇
  2010年   132篇
  2009年   118篇
  2008年   144篇
  2007年   128篇
  2006年   140篇
  2005年   120篇
  2004年   114篇
  2003年   107篇
  2002年   103篇
  2001年   83篇
  2000年   95篇
  1999年   52篇
  1998年   71篇
  1997年   39篇
  1996年   37篇
  1995年   60篇
  1994年   44篇
  1993年   35篇
  1992年   37篇
  1991年   39篇
  1990年   41篇
  1989年   45篇
  1988年   22篇
  1987年   26篇
  1986年   39篇
  1985年   49篇
  1984年   33篇
  1983年   15篇
  1982年   16篇
  1981年   16篇
  1980年   12篇
  1979年   15篇
  1978年   8篇
  1977年   6篇
  1976年   5篇
  1973年   3篇
排序方式: 共有3588条查询结果,搜索用时 15 毫秒
1.
2.
3.
前列腺偶发癌(IPC)临床常见脾肾两虚、湿热毒蕴、痞热瘀结、气阴两虚等证型,中医药治疗IPC不离扶正祛邪之宗旨,法当调节免疫以扶正、减毒抗癌以祛邪。结合国医名师徐荷芬临床诊疗经验,以"扶正固本、养阴祛瘤"学术思想为纲,"期型分治"为目,探讨IPC不同时期不同证型的辨治方法,概括为温脾补肾、清热燥湿、化痞破瘀、益气养阴等治法;强调带瘤生存,引入生存质量评价,生存质量应包含生活质量和患者满意度,完善IPC疗效评价体系。  相似文献   
4.

Aims

Delaying progression, ameliorating symptoms and maintaining quality of life (QoL) are primary aims of treatment for metastatic castrate-resistant prostate cancer (mCRPC). Real-world rather than clinical trial data about symptoms and side-effects are sparse. In EXTREQOL, patients' QoL, pain and information needs were recorded during treatment.

Material and methods

Men with mCRPC from 20 UK cancer centres starting various systemic mCRPC treatments completed QoL, pain and information needs questionnaires at baseline, 3 and 6 months.

Results

In total, 132 patients were recruited. Overall QoL declined significantly by 6 months (Functional Assessment of Cancer Therapy-Prostate [FACT-P] mean = –3.89, 95% confidence interval –6.7 to –1.05, P = 0.007; Trial Outcome Index [TOI] analysis mean = –3.10, 95% confidence interval –5.34 to –0.83, P = 0.007). Those who came off novel therapy and remained on luteinising hormone-releasing hormone agonist therapy alone had worse scores than patients receiving concomitant chemotherapy (Prostate Concerns Subscale mean difference = –4.45, 95% confidence interval –7.06 to –1.83, P = 0.001; TOI mean difference = –5.62, 95% confidence interval –10.97 to –0.26, P = 0.040). At 3 and 6 months, men who reported pain at baseline improved (43%, 40%), but for others pain levels remained the same (45%, 42%) or worsened (13%, 18%). Information regarding supportive care was lacking throughout the period of time on the study.

Conclusion

Most mCRPC treated patients experience reduced QoL and inadequate pain control. More help with pain management and better information provision regarding supportive care is warranted.  相似文献   
5.
6.
7.
The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR‐MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis‐stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P < .001). Infection‐related severe adverse events were observed in more than 20% of patients treated with AZA. Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients.  相似文献   
8.
复发性流产是一种常见妊娠并发症,病因复杂多样,其中内分泌因素占8%~12%,文章主要就甲状腺功能异常、高催乳素血症、多囊卵巢综合征及代谢异常、糖尿病、黄体功能不全等内分泌因素进行综述,旨在为复发性流产的预防及治疗方面带来新的思考。  相似文献   
9.
The endocrine system relies on the vasculature for delivery of hormones throughout the body, and the capillary microvasculature is the site where the hormones cross from the blood into the target tissue. Once considered an inert wall, various studies have now highlighted the functions of the capillary endothelium to regulate transport and therefore affect or maintain the interstitial environment. The role of the capillary may be clear in areas where there is a continuous endothelium, yet there also appears to be a role of endothelial cells in tissues with a sinusoidal structure. Here we focused on the most common endocrine disorder, diabetes, and several of the target organs associated with the disease, including skeletal muscle, liver and pancreas. However, it is important to note that the ability of hormones to cross the endothelium to reach their target tissue is a component of all endocrine functions. It is also a consideration in organs throughout the body and may have greater impact for larger hormones with target tissues containing a continuous endothelium. We noted that the blood levels do not always equal interstitial levels, which is what the cells are exposed to, and discussed how this may change in diseases such as obesity and insulin resistance. The capillary endothelium is, therefore, an essential and understudied aspect of endocrinology and metabolism that can be altered in disease, which may be an appropriate target for treatment.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号